n.a. (PVA: NYSE)
$n/a n/a | n/a%
12/31/69 - 07:00 PM ET
Growth Rates data is not available for PVA.
Portfolios with PVA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorNatural Gas Stock Trades Th...
- UserThe First One
- Contributor7 Marcellus Shale Plays to ...
- Contributor9 Marcellus Shale Stocks Wi...
- Contributor10 Small-Caps Expected to R...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Research Reports 8...
- UserBarrons Interview With Jim ...
Latest PVA Headlines from TheStreet
- Penn Virginia (PVA) Stock Closes Higher on Rising Oil Prices 08.28.15 | 04:08 pm
- 6 Stocks Under $10 to Trade for Breakouts 08.27.15 | 01:08 pm
- Penn Virginia (PVA) Stock Gets Rating Downgrade at Credit Suisse 08.07.15 | 01:08 pm
- Penn Virginia Corporation Engages Jefferies LLC As Exclusive Financial Advisor For Certain Eagle Ford-Related Transactions 08.04.15 | 10:08 am
- Penn Virginia (PVA) Stock Falls as Oil Prices Tumble 08.03.15 | 12:08 pm
- Penn Virginia (PVA) Stock Closes Down as Oil Prices Fall 07.31.15 | 04:07 pm
- Penn Virginia Corporation Announces Second Quarter 2015 Results And Provides Updates Of 2015 Guidance And Operations 07.29.15 | 04:07 pm
- Penn Virginia (PVA) Stock Higher Amid Rally in Oil Prices 07.29.15 | 02:07 pm
- Penn Virginia (PVA) Showing Signs Of A Dead Cat Bounce Today 07.23.15 | 09:07 am
- Penn Virginia Corporation Chief Executive Officer And President Baird Whitehead Announces Retirement; Board Commences Chief Executive Officer Search 07.20.15 | 04:07 pm
Press Releases for PVA
- PSivida CEO To Speak At Controlled Release Society Annual Meeting Workshop In Edinburgh, Scotland, This Weekend - Business Wire 07.21.15 | 08:07 am
- PSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study Of Medidur™ For Uveitis - Business Wire 07.13.15 | 07:07 am
- PSivida Announces Top-Line Results From Investigator-Sponsored Phase II Study Of Medidur™ For Uveitis To Be Reported Next Week - Business Wire 07.07.15 | 11:07 am
- Lone Star Value Calls On Penn Virginia To Launch A Robust Strategic Alternatives Review Process And Fully Explore All Credible Proposals - PR Newswire 06.26.15 | 01:06 pm
- PSivida CEO To Present At ISOPT Clinical Meeting In Berlin In July 2015 - Business Wire 06.24.15 | 07:06 am
- PSivida Reports Positive IOP Safety Data In Phase III Trial Of Medidur™ For Posterior Uveitis - Business Wire 05.19.15 | 07:05 am
- PSivida Announces Two Tech Evaluation Agreements With Leading Global Pharmaceutical Company - Business Wire 05.12.15 | 07:05 am
- PSivida Corp. Reports Third Quarter FY 2015 Results - Business Wire 05.08.15 | 07:05 am
- PSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date And Conference Call Information - Business Wire 05.01.15 | 08:05 am
- PSivida Corp. Reports ILUVIEN® For DME Approved In Poland - Business Wire 04.14.15 | 08:04 am
Partner Headlines for PVA
- Penn Virginia downgraded to Hold from Buy at Canaccord - The Fly 11.11.15 | 06:11 am
- Penn Virginia downgraded to Hold from Buy at KLR Group - The Fly 10.15.15 | 08:10 am
- Penn Virginia downgraded to Underweight from Equalweight at Capital One - The Fly 09.09.15 | 09:09 am
- Penn Virginia downgraded to Neutral from Outperform at Credit Suisse - The Fly 08.07.15 | 07:08 am
- Penn Virginia price target lowered to $3.75 from $8.50 at Canaccord - The Fly 08.03.15 | 07:08 am
- Penn Virginia downgraded to Sector Perform from Outperform at Scotia - The Fly 07.30.15 | 09:07 am
- Soros Left in Lurch as Penn Virginia Misses Window: Real M&A - Bloomberg 07.22.15 | 06:07 pm
- Penn Virginia stock should outperform on asset sale, says SunTrust - The Fly 07.16.15 | 07:07 am
- Penn Virginia downgraded to In-Line from Outperform at Imperial Capital - The Fly 07.15.15 | 05:07 am
- Penn Virginia says seeing interest in East Texas assets, says RBC Capital - The Fly 06.12.15 | 08:06 am